IBRX · ISSUER CIK 1326110
ImmunityBio, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 ImmunityBio, Inc. insiders reported $0.00 of open-market purchases and $1.1M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.1MInsider selling
−$1.1MNet open-market
Oct 6, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 202618:06 | Oct 5, 2026 | IBRX | Director | S · Sell10b5-1 | $10.75 | −25,000 | 2,777,788 | -1% | −$269K | ||
| Oct 6, 202618:05 | Oct 2, 2026 | IBRX | Director | S · Sell10b5-1 | $10.50 | −81,056 | 100,309 | -45% | −$851K | ||
| Oct 6, 202618:05 | Oct 2, 2026 | IBRX | Director | M · Exercise10b5-1 | $2.98 | +55,979 | 181,365 | +45% | $167K |